We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 35% over five years while the S&P 500 rose 72%; up 23% in the past year.
“Q3 loss from operations was $29.5 million primarily driven by intangible asset impairment charge, compared to income from operations of $16.8 million.”
| The company | Sales up 14% on the year |
| Its score | Up:Above Average or better for 71 days in a row |
| Latest filing | 8-K, Nov 6 |
Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.
After its last 4 reports it closed +3.5% on average, higher 2 of 4 times.
Above Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
RGEN is #44 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 44 |
Net income over four quarters: RGEN -$11.8M, TECH $172M, NBIX $702M, ADMA $182M.
Expected to report Tue Feb 23, before the open (in 105 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $209.3M, 11% more than a year ago; a loss of $0.68 a share, from a profit of $0.26.
“Q3 loss from operations was $29.5 million primarily driven by intangible asset impairment charge, compared to income from operations of $16.8 million.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $209M | $204M | $189M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 30)
| Measure | Figure |
|---|---|
| Revenue | $844M to $852M |
Sales grew 15% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 27, 2026 | -6.6% | -2.4% | -4.0% |
| Jul 28, 2026 | +6.6% | +10.9% | +12.2% |
| May 5, 2026 | +2.6% | +6.3% | -1.9% |
Sales grew in six of the last seven years, to $738M in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 47.5, MACD below signal, below its 50-day, above its 200-day. Not scored.
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: RGEN is under 0.1% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
RGEN scores 11 today, which Breakaway calls Above Average. It is #44 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 35% over five years while the S&P 500 rose 72%; up 23% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
RGEN scores 11 today, which Breakaway calls Above Average (11 to 14). That is #44 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RGEN's 11.
Expected to report Tue Feb 23, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. RGEN closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.